RPRX vs. RVMD: Royalty Pharma vs. Revolution Medicines Stock Comparison

Company Profile

Royalty Pharma (RPRX) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RPRX is classified in Pharmaceuticals while RVMD is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Revolution Medicines (RVMD) has an aggressive beta of 1.42, indicating higher sensitivity to broad-market moves, while Royalty Pharma (RPRX) is defensive at 0.36 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Royalty Pharma (RPRX) reports 12.09%, ranking against industry peers normally.

Royalty Pharma (RPRX) at 25.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Royalty Pharma (RPRX) reports 81.32%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Royalty Pharma (RPRX) reports revenue growth of 5.06%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Royalty Pharma (RPRX) reports EPS growth of 23.09%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.

Revolution Medicines (RVMD) at 0.50 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Revolution Medicines (RVMD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

Revolution Medicines (RVMD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Royalty Pharma (RPRX) trades at 43.99 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Royalty Pharma (RPRX) at 14.79 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Royalty Pharma (RPRX) at 4.39 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

Valuation Metrics